V Prokic1, H Geinitz, P Kneschaurek. 1. Klinik und Poliklinik für radiologische Onkologie, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. vesna.prokic@uniklinik-freiburg.de
Abstract
BACKGROUND: In this study, the interplay between intrafractional prostate motion and helical tomotherapy (HT) radiation delivery with respect to treatment planning parameters, such as jaw size and pitch factor, was investigated. METHODS: Four treatment plans were created using two jaw widths (i.e., 1.05 and 2.5 cm) and two pitch factors (i.e., 0.287 and 0.574). A phantom with a slit for a film, attached to the motion platform, was used to simulate two-dimensional prostate motion in the superior-inferior and anterior-posterior directions. Doses were measured using gafchromic EBT films in the sagittal position. Each treatment plan was delivered to the static and dynamic phantom. Dose measurements performed with the dynamic phantom were quantitatively compared to static phantom doses in terms of dose-area histograms (DAH) for the planning target volume (PTV) and prostate, percentage of prostate and PTV receiving the prescription dose, and the minimum dose received by 95% of the prostate. RESULTS: Larger jaw width (2.5 cm) provided more adequate coverage of the PTV and prostate: D(95) of the moving prostate was 1.9 Gy for both plans with the jaw size 2.5 cm. When the jaw size was 1.05 cm, D(95) of the prostate and the PTV dropped to 1.5 Gy and 1.4 Gy, respectively. For a given jaw size, prostate and PTV dose coverage do not appear to be significantly dependent on the pitch factor. CONCLUSION: In the absence of an optimal motion management technique, the correct choice of the planning parameters is important to overcome larger under- and overdosage caused by intrafractional prostate motion during HT.
BACKGROUND: In this study, the interplay between intrafractional prostate motion and helical tomotherapy (HT) radiation delivery with respect to treatment planning parameters, such as jaw size and pitch factor, was investigated. METHODS: Four treatment plans were created using two jaw widths (i.e., 1.05 and 2.5 cm) and two pitch factors (i.e., 0.287 and 0.574). A phantom with a slit for a film, attached to the motion platform, was used to simulate two-dimensional prostate motion in the superior-inferior and anterior-posterior directions. Doses were measured using gafchromic EBT films in the sagittal position. Each treatment plan was delivered to the static and dynamic phantom. Dose measurements performed with the dynamic phantom were quantitatively compared to static phantom doses in terms of dose-area histograms (DAH) for the planning target volume (PTV) and prostate, percentage of prostate and PTV receiving the prescription dose, and the minimum dose received by 95% of the prostate. RESULTS: Larger jaw width (2.5 cm) provided more adequate coverage of the PTV and prostate: D(95) of the moving prostate was 1.9 Gy for both plans with the jaw size 2.5 cm. When the jaw size was 1.05 cm, D(95) of the prostate and the PTV dropped to 1.5 Gy and 1.4 Gy, respectively. For a given jaw size, prostate and PTV dose coverage do not appear to be significantly dependent on the pitch factor. CONCLUSION: In the absence of an optimal motion management technique, the correct choice of the planning parameters is important to overcome larger under- and overdosage caused by intrafractional prostate motion during HT.
Authors: Katja M Langen; Weiguo Lu; Wilfred Ngwa; Twyla R Willoughby; Bhavin Chauhan; Sanford L Meeks; Patrick A Kupelian; Gustavo Olivera Journal: Phys Med Biol Date: 2008-11-18 Impact factor: 3.609
Authors: Frederik Wenz; Thomas Martin; Dirk Böhmer; Stefan Martens; Felix Sedlmayer; Manfred Wirth; Kurt Miller; Axel Heidenreich; Mark Schrader; Wolfgang Hinkelbein; Thomas Wiegel Journal: Strahlenther Onkol Date: 2010-09-30 Impact factor: 3.621
Authors: T R Mackie; T Holmes; S Swerdloff; P Reckwerdt; J O Deasy; J Yang; B Paliwal; T Kinsella Journal: Med Phys Date: 1993 Nov-Dec Impact factor: 4.071
Authors: Katja M Langen; Twyla R Willoughby; Sanford L Meeks; Anand Santhanam; Alexis Cunningham; Lisa Levine; Patrick A Kupelian Journal: Int J Radiat Oncol Biol Phys Date: 2008-02-14 Impact factor: 7.038
Authors: Johanne Hermesse; Sylvie Biver; Nicolas Jansen; Eric Lenaerts; Nathalie De Patoul; Stefaan Vynckier; Philippe Coucke; Pierre Scalliet; Philippe Nickers Journal: Strahlenther Onkol Date: 2009-11-10 Impact factor: 3.621
Authors: Felix Zwicker; Benedict Swartman; Falk Roeder; Florian Sterzing; Henrik Hauswald; Christian Thieke; Klaus-Josef Weber; Peter E Huber; Kai Schubert; Jürgen Debus; Klaus Herfarth Journal: J Radiat Res Date: 2014-10-31 Impact factor: 2.724